ClinicalTrials.govpublic full text
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
non small cell lung cancer, stage iv non-small cell lung cancer, recurrent non small cell lung cancer, lung cancer, tumor-infiltrating lymphocytes, egfr mutation, alk rearrangement, ros1 rearrangement, erbb2 mutation, her2 exon 20 mutation, interventional, phase1
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 836486
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.